Medpace reported third-quarter revenue of $716 million, up 8.5% year over year, while net new business awards rose 10.6% to $873 million. Medpace kept the midpoint of its 2026 revenue guidance at nearly $2.85 billion, but raised its midpoint EBITDA outlook by 2.4% to $645 million.
Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.
Significant pullbacks in biotech funding or declines in outsourcing penetration rates have a material impact on Medpace's growth.
|
Metric
|
MEDP
|
IQV
|
FTRE
|
|---|---|---|---|
Price/Earnings (Normalized) | 39.67 | 21.94 | 178.26 |
Price/Book Value | 32.36 | 7.30 | 4.32 |
Price/Sales | 6.85 | 2.74 | 0.83 |
Price/Cash Flow | 30.50 | 17.78 | 42.42 |
|
Metric
|
MEDP
|
IQV
|
FTRE
|
|---|---|---|---|
Quick Ratio | 0.77 | 0.62 | 0.85 |
Current Ratio | 0.83 | 0.71 | 0.96 |
Interest Coverage | — | 2.99 | 0.08 |
|
Metric
|
MEDP
|
IQV
|
FTRE
|
|---|---|---|---|
Return on Assets (Normalized) | 26.25% | 7.22% | 2.15% |
Return on Equity (Normalized) | 113.17% | 34.41% | 10.56% |
Return on Invested Capital (Normalized) | 87.02% | 12.37% | 7.32% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|n^@@#!!@ | LOCK|^! | $253B | |||
| Danaher Corp
DHR
| LOCK|v<$#Q>#< | LOCK|qwk | $164B | |||
| Agilent Technologies Inc
A
| LOCK|<#^>Rby? | LOCK|^z | $50B | |||
| IQVIA Holdings Inc
IQV
| LOCK|Xhpf@v | LOCK|#!^# | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|!^jQ%G^ | LOCK|S?$ | $45B | |||
| Waters Corp
WAT
| LOCK|PH!Rk%y | LOCK|S>W | $45B | |||
| Illumina Inc
ILMN
| LOCK|$!Sv<P@ | LOCK|!&F? | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|B&>T!&% | LOCK|^$!@ | $33B | |||
| Quest Diagnostics Inc
DGX
| LOCK|qX@>$T& | LOCK|BkW< | $27B | |||
| Labcorp Holdings Inc
LH
| LOCK|<&%%F@r< | LOCK|K@BD | $27B |
United States